💸 The Tape

Cronos just paid €57.5 million for the biggest grower in Europe’s only legal adult-use supply chain. Village Farms built one from scratch. Both are betting on the same thing: that ten municipalities become the whole country.

For fifty years, the Netherlands ran the strangest cannabis policy in the world. Coffeeshops could sell at the front door under the gedoogbeleid, the tolerance policy, while everything that arrived at the back door was illegal. The product on the shelf was untested, untaxed, and sourced from whoever could grow it without getting caught. The Dutch called this pragmatism. Everyone else called it a loophole with a menu.

The Wietexperiment is the attempt to close the back door. Parliament passed the enabling law in 2019, licensed ten growers in 2022, and after a three-year transition flipped the switch on April 7, 2025: coffeeshops in ten participating municipalities now sell only product from the ten licensed cultivators. Regulated hash was added in September 2025. Import and export are prohibited, growers cannot sell to each other, and product can only move to coffeeshops inside the experiment’s footprint. It is a sealed loop by design.

The footprint, and the ceiling

That footprint is the whole story. The ten municipalities, Almere, Arnhem, Breda, Groningen, Heerlen, Maastricht, Nijmegen, Tilburg, Voorne aan Zee and Zaanstad, hold about 1.7 million residents and 69 coffeeshops. The Netherlands has 18.1 million people and 562 coffeeshops. Amsterdam is not in. So the legal chain today serves roughly 12 percent of the retail base, with ten growers competing for it.

The experiment runs through 2029, when the national government evaluates and decides whether regulated cultivation becomes permanent policy. An interim report from the Justice Ministry’s research arm, published September 9, called early experience predominantly positive while noting the full effects cannot yet be measured. The first-year reviews were similar: early shortages of popular strains resolved, quality and variety now consistent, coffeeshop sales holding, no visible shift to street dealing. The hash transition has been bumpier, since legal hash tastes different and costs more than the Moroccan supply it replaced, though retailers say most customers have switched.

Enforcement has teeth. Inspectors ran 46 grower inspections in 2025 and found 42 violations, mostly registry and security lapses, resulting in four fines between €1,000 and €20,000. The inspectorate said the problems went beyond simple error but found no sign of criminal involvement, which in Dutch cannabis policy counts as a glowing review.

The pressure now is on the calendar. Breda’s mayor wants the tolerance policy gone within four years rather than waiting on 2029. Researchers warn that ending the experiment would trigger chaos and litigation, given that growers have invested millions on the promise of a market. Only a handful of parties in parliament opposed the experiment in the first place. The political question is no longer whether it survives, but how fast it grows.

Business case one: Cronos buys the leader

On Wednesday, Cronos closed its acquisition of CanAdelaar, the largest of the ten licensed growers and, by Cronos’s description, Europe’s largest adult-use cannabis company. The numbers explain why it was worth buying.

CanAdelaar runs a 540,000-square-foot greenhouse in Voorne aan Zee with roughly 20,000 kilograms of annual flower capacity. It is the only greenhouse operator among the ten licensees; the rest grow indoors, which means CanAdelaar has the lowest cost structure in a market with a fixed number of customers. It supplies nearly all 69 participating coffeeshops and holds the top share by volume and revenue. Sales began in Q4 2023. Revenue went from €15.2 million in 2024 to €40.6 million for the twelve months ending September 2025, and the first half of 2026 annualizes to €41.6 million.

Cronos paid €57.5 million base, plus an earnout of half of normalized EBITDA for 2026 and 2027. On first-half annualized figures, that is 1.4x revenue and 2.9x adjusted EBITDA. In any other cannabis market that would be a distressed multiple. Here it reflects something more specific: CanAdelaar’s adjusted EBITDA peaked at €24.2 million on a trailing basis and has settled to about €20 million annualized, and Cronos says plainly why. All ten growers are now fully operational and competing for the same 69 shops. Margins compressed from roughly 60 percent to under 50 percent as the market filled in.

CEO Mike Gorenstein called it “a meaningful and scalable platform in Europe’s largest adult-use cannabis market” and said the plan is to bring Cronos’s genetics and brands, including derivative products the program allows, to Dutch consumers. The release also says the quiet part: expansion to more municipalities or nationwide “could significantly grow the addressable market.” Cronos is buying the current market at a modest multiple and the future market for free.

Business case two: Village Farms builds its own

Village Farms took the organic route through its licensee, Leli Holland. Phase I in Drachten came online first; Phase II in Groningen began cultivation in June after final approvals and is expected to reach full production by the end of the first quarter of 2027, taking total Dutch capacity to about 10 metric tonnes annualized. The company has pushed into formats, launching pre-rolls, blunts and spliffs into a market that historically bought flower and rolled its own.

The revenue line is still small. Netherlands branded net sales were $3.3 million in Q2 2026, up 35 percent from $2.5 million a year earlier, inside a cannabis segment doing $53.5 million a quarter. That is a capacity story, not a demand story. CanAdelaar built big first and is now defending share; Village Farms is still adding supply into a market it has barely scratched, with CEO Michael DeGiglio guiding to profitable Dutch sales through 2026 and beyond.

What the two cases say together

Read side by side, Cronos and Village Farms describe the same market from opposite ends. The legal chain is real, profitable and growing, but bounded by ten municipalities and a 2029 decision. Ten growers chasing 69 shops means share and cost now matter more than capacity, which favors the greenhouse. The only growth lever that changes the math is geographic expansion, and that lever belongs to The Hague, not the operators.

Cronos paid roughly three times EBITDA for the leader. Village Farms is spending capital to be ready when the fence moves. One of them is early. The 2029 evaluation, or a cabinet that decides not to wait that long, will say which.

📈 Dog Walkers

$CURLF ( ▼ 1.87% ) Relocates In PA

Curaleaf opened a new medical dispensary in York, Pennsylvania on Thursday, relocating its Gettysburg store roughly 30 miles east to 1513 N. George Street, near Interstate 83 and U.S. Route 30. Soft opening was Thursday at 1 p.m.; the grand opening runs Friday, October 23, with the standard playbook of food truck, music, brand pop-ups and a free tote for card-holding patients.

The headline number is the one that didn’t change: Curaleaf still has 18 dispensaries in Pennsylvania and 189 nationwide. This is a swap, not an expansion. The company is taking a license out of a county anchored by a battlefield and tourist traffic and dropping it into one with 456,000 residents and two highways running through it. York itself has about 45,000 people, with Springettsbury, North York and Manchester all within a short drive.

Chairman and CEO Boris Jordan kept the framing on access: “With Curaleaf York, we’re putting quality products and real guidance within a short drive for patients across York County.” The store will carry the full house portfolio, including Grassroots, FIND, Select, JAMS, Dark Heart and the new Select Briq 2 all-in-one vape, with hours running 9 to 8 Monday through Saturday and 10 to 6 on Sundays.

The release says nothing about why Gettysburg didn’t work, and nothing about Pennsylvania’s broader market, which leaves the subtext to do the talking. Multi-state operators with mature footprints have spent the past two years treating dispensary licenses as portable assets rather than fixed ones, closing or shifting underperforming doors toward denser trade areas. A relocation announced with a grand-opening party is the friendliest version of that process.

For patients in York County, it is a new store with a familiar brand lineup. For investors, it is a small, sensible move that tells you where Curaleaf thinks the demand is, and where it isn’t.

📺 Trade To Black

From Organigram Cuts to Question 8 Funding | TTB presented by Flowhub

• Organigram CEO James Yamanaka (NASDAQ: OGI, TSX: OGI) on the completed Sanity Group integration and the new unified global operating model, targeting $8–10 million in annualized savings, $5–6 million of it landing in fiscal 2027 against roughly $2 million in one-time costs.

• Dr. Paul Shields, Chief Medical Officer at Vantage Hemp, returns for the weekly Vantage Standard segment, revisiting recent topics with a fresh angle.

• FundCanna CEO Adam Stettner follows the money behind Massachusetts Question 8, the November 3 ballot measure to repeal regulated adult-use sales: state filings show the Coalition for a Healthy Massachusetts has raised about $3.5 million, roughly 98.5% from SAM Action Inc., a Virginia nonprofit.

• Who the other donors are, how little came from Massachusetts residents, and what that says about the campaign, set against a recent MassINC poll showing 61% of likely voters opposed to repeal and 27% in favor.